Business Context and Reporting Period
Company: Predictive Oncology Inc. (POAI)
Reporting Period: Quarter ended March 31, 2025
Business Overview: The Company is a knowledge-driven entity applying artificial intelligence (AI) to oncology drug discovery using a proprietary biobank of 150,000+ tumor samples and 3D cell culture models. Following the disposal of its Eagan operating segment (STREAMWAY product line) and the prior discontinuation of its Birmingham segment, the Company now operates as a single segment focused on AI-driven cancer therapy development.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue (Continuing Ops) | $110,310 | $4,858 |
| Gross Profit | $65,192 | $(17,575) |
| Operating Loss | $(2,287,047) | $(3,582,034) |
| Net Loss (Continuing Ops) | $(2,285,416) | $(3,564,105) |
| Net Loss (Total) | $(2,442,873) | $(4,218,843) |
| Cash and Equivalents (End of Period) | $3,087,588 | $4,734,628 |
| Accumulated Deficit | $(182,869,144) | $(171,980,726) |
| Stockholders' Deficit | $(145,796) | $4,053,671 |
Liquidity & Debt: The Company holds $3.09 million in cash. Total current liabilities are $4.61 million, and long-term lease obligations are $1.41 million. There is no traditional debt listed, but significant lease liabilities exist.
Material Changes vs. Prior Period
- Revenue Growth: Revenue from continuing operations increased by $105,452 (2,170% increase) primarily due to the completion of a tumor-specific 3D model in Q1 2025, whereas none were completed in Q1 2024.
- Expense Reduction: Total operating expenses decreased by $1.21 million. Significant reductions occurred in Sales and Marketing ($605k decrease) and General & Administrative ($497k decrease) due to headcount reductions and lower professional fees.
- Discontinued Operations: The Company sold its Eagan business assets to DeRoyal Industries for $625,000, resulting in a gain on disposal of $172,451. This segment is now reported as discontinued operations.
- Capital Structure: The Company raised approximately $2.58 million in gross proceeds through warrant exercises, a Registered Direct Offering ($545k), and a subscription agreement with Renovaro ($500k). Common shares outstanding increased from 6.67 million to 8.93 million.
Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for one year from the filing date. The Company requires significant additional capital to meet operating needs and does not expect to generate sufficient revenue to sustain operations in the near term.
- Failed Merger & Litigation: A proposed merger with Renovaro Inc. terminated on March 31, 2025. On May 8, 2025, Renovaro filed a lawsuit in Delaware Chancery Court alleging breach of contract and seeking to compel the merger. The Company intends to contest this vigorously.
- NASDAQ Compliance: The Company received a notice of non-compliance regarding the minimum stockholders' equity requirement ($2.5 million). As of March 31, 2025, stockholders' equity was a deficit of $145,796. The Company is evaluating options to regain compliance to avoid delisting.
- Customer Concentration: 93% of Q1 2025 revenue from continuing operations was derived from a single customer.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.09 million cash balance against the $4.61 million in current liabilities and ongoing burn rate of ~$1 million per quarter.
- Legal Exposure: Monitor the status of the lawsuit filed by Renovaro Inc. and potential costs or injunctions that could impact operations.
- Listing Status: Confirm the Company's progress in regaining compliance with NASDAQ stockholders' equity requirements to prevent delisting.
- Revenue Sustainability: Assess the likelihood of recurring revenue from the single customer representing 93% of Q1 sales.
- Dilution Risk: Review terms of future financing, as the Company may need to issue equity on dilutive terms to secure liquidity.